In addition, among patients with PRAD with an enriched oxidative phosphorylation signature, the group with relatively lower NOTCH2-DEG enrichment scores exhibited more prolonged survival (S23 Fig in S1 File). The gene discussed is NOTCH2; the disease is prostate adenocarcinoma.